Search
Inetetamab
go.drugbank.com/drugs/DB17457InvestigationalIt differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.
Grazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Pargyline
go.drugbank.com/drugs/DB01626ApprovedPargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Domperidone
go.drugbank.com/drugs/DB01184ApprovedInvestigationalVet approvedA specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-ph...
Rimiducid
go.drugbank.com/drugs/DB04974InvestigationalIt was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.
Candesartan cilexetil
go.drugbank.com/drugs/DB00796ApprovedInvestigationalCandesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents
Boron
go.drugbank.com/drugs/DB11203ApprovedInvestigationalNatural boron exists in 2 stable isotopes however pure boron is hard to prepare due to contamination by different elements.
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigational[L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence
ABX-PTH
go.drugbank.com/drugs/DB05883ExperimentalABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform.